DKDemet Yilmaz Karadag

Demet Yilmaz Karadag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Demet Yilmaz Karadag has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Cornelian Cherry on Microbiota in Male Professional Football Players

    by Emre Batuhan Kenger, Tuğçe Özlü Karahan, Demet Yılmaz Karadag, Fatih Eren, Fatma Esra Güneş

    This study aimed to investigate the effects of lyophilized cornelian cherry supplementation on gut microbiota composition in male professional football players aged 18–37 years recruited from a football club competing in the Turkish Football Federation Second League in Istanbul, Türkiye. The participating football players received 30 g of cornelian cherries containing 350 mg of anthocyanins for six weeks. The fecal microbiota communities of the football players were analyzed using the 16S rRNA gene sequencing. Moreover, their nutritional status, body compositions, and vertical jump performance were assessed. In the cornelian cherry group, the median relative abundance of Parabacteroides goldsteinii increased from 0.06% (0.01–0.17%) at baseline to 0.37% (0.11–15.44%) at week 6 (p = 0.005). Similarly, median body fat percentage decreased from 10.8% (5.0–16.2%) to 9.6% (4.0–14.6%) (p = 0.019), while median vertical jump height increased from 37.7 cm (31.9–46.5 cm) to 39.3 cm (34.6–49.0 cm) (p = 0.005). However, the between-group difference in the absolute change in Parabacteroides goldsteinii relative abundance was not statistically significant (p = 0.190). Cornelian cherry supplementation was not associated with significant changes in gut microbial alpha or beta diversity. However, an increase in the relative abundance of Parabacteroides goldsteinii, along with changes in body composition and vertical jump performance, was observed in the intervention group. These preliminary findings suggest that changes in selected microbial, anthropometric, and performance outcomes occurred during the intervention, although supplementation-specific effects cannot be established. Larger, placebo-controlled trials are warranted to confirm these observations.

  • Open Access

    Frequency and Potential Disease-Modifying Role of MEFV Variants in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Case–Control Study

    by Ömer Işık, Fatih Eren, Ahmet Mert Yanık, Fatma Arıkan, Asu Fergün Yılmaz, Tayfur Toptaş, Mehmet Pamir Atagündüz, Demet Yılmaz Karadağ, Işık Atagündüz

    Background and Objectives: Familial Mediterranean Fever (MEFV) gene variants exhibit a high carrier frequency in the Turkish population and modulate clinical phenotypes through persistent low-grade innate immune activation. However, their role in myeloid malignancies—where aberrant inflammasome signaling contributes to immunopathogenesis—remains poorly defined. We aimed to investigate the carrier frequency and potential disease-modifying role of common MEFV variants in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Materials and Methods: In this retrospective case–control study, 80 clinical evaluations from 75 unique patients with myeloid malignancies (53 AML and 27 MDS, including 5 patients evaluated in both cohorts before and after leukemic transformation) and 186 healthy controls from the Turkish population were analyzed. Four established pathogenic exon 10 variants (M694V, V726A, M680I, and M694I) and two variants of uncertain significance (VUS; K695R and E148Q) were genotyped using rhAmp™ SNP Genotyping and polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) assays. Clinical characteristics, blastic progression, and survival outcomes were evaluated. Results: Overall MEFV variant carriage did not differ significantly between the unique patient cohort and healthy controls (24.0% [18/75] vs. 19.9% [37/186], p = 0.462; or 23.8% [19/80] across all disease evaluations, p = 0.479). In the MDS cohort (n = 27), 10 mutant alleles were detected in 9 unique patients (variant frequency: 37.0% vs. 19.9% in controls, p = 0.045; unique carrier frequency: 33.3% vs. 19.9%, p = 0.113), as one female MDS patient was a compound heterozygote (M694V/V726A). Stratified analysis revealed that this enrichment in MDS was driven by established pathogenic exon 10 variants (22.2% [6/27] vs. 9.1% [17/186], p = 0.041; allele frequency: 11.1% [6/54] vs. 4.6% [17/372], p = 0.047), whereas VUS frequencies were comparable (14.8% vs. 10.8%, p = 0.533). Within the MDS group, male patients showed an exploratory trend toward a higher carrier rate than females (60.0% [6/10] vs. 17.6% [3/17], Fisher’s exact p = 0.039). Conversely, MEFV variant frequency in AML mirrored that of controls (20.8% [11/53] vs. 19.9%, p = 0.890). Baseline clinical parameters and overall survival did not differ significantly by genotype, although MEFV-positive MDS patients exhibited a non-significant numerical trend toward a shorter interval to blast progression (12.7 vs. 36.2 months). Conclusions: Our findings provide exploratory, hypothesis-generating evidence suggesting a potential enrichment of pathogenic exon 10 MEFV variants in MDS—particularly among male patients—but not in AML. Given the small sample size and retrospective design, these observations require validation in larger multi-center cohorts, and future studies may explore whether MEFV genotyping offers clinical or prognostic utility in high-prevalence populations.

  • Open Access

    BALAD-2 Emerges as the Most Accurate Prognostic Model in Hepatocellular Carcinoma: Results from a Biobank-Based Cohort Study

    by Coskun Ozer Demirtas, Fatih Eren, Demet Yilmaz Karadag, Yasemin Kaldirim Armutcuoglu, Tugba Tolu, Javid Huseyinov, Ugur Ciftci, Tuba Yilmaz, Sehnaz Akin, Feyza Dilber, et al.

    Background/Objectives: Accurate prognostication of hepatocellular carcinoma (HCC) remains essential for treatment selection and risk stratification. This study aimed to compare the prognostic performance of individual serum biomarkers and composite scoring models, including GALAD, BALAD, BALAD-2, GAAP, ASAP, the Doylestown algorithm, and aMAP, using data from a biobank-based HCC cohort. Methods: This study enrolled 186 patients with confirmed HCC diagnosed between 2019 and 2024. Serum biomarkers (AFP, AFP-L3%, DCP) and composite models were evaluated for their association with overall survival (OS). Prognostic performance was assessed using time-dependent area under the receiver operating characteristic curve (AUROC) at 1-, 2-, 3-, and 5-year intervals and Harrel’s concordance index (c-index). Subgroup analyses were performed based on treatment intent and liver disease etiology. Results: All three biomarkers and composite models were independently associated with OS in multivariate analyses (all p < 0.05). Among all models, BALAD-2 demonstrated the best overall performance (c-index: 0.737), with the highest AUROCs at 1 year (0.827), 2 years (0.846), 3 years (0.781), and 5 years (0.716). BALAD-2 consistently showed superior discrimination in patients treated with curative or noncurative therapies and in the viral etiology subgroup. In the non-viral etiology subgroup, BALAD-2 remained among the top performers, although the GAAP, ASAP, and Doylestown algorithms showed slightly higher metrics. Conclusions: BALAD-2 demonstrated consistent and robust prognostic performance compared with other biomarker-based and clinical models across different patient subgroups, particularly among those receiving curative therapy and viral etiologies. These findings support its integration into clinical risk stratification and decision-making for HCC management.


  • Open Access

    Enhancing Hepatocellular Carcinoma Surveillance: Comparative Evaluation of AFP, AFP-L3, DCP and Composite Models in a Biobank-Based Case-Control Study

    by Coskun O. Demirtas, Sehnaz Akin, Demet Yilmaz Karadag, Tuba Yilmaz, Ugur Ciftci, Javid Huseynov, Tugba Tolu Bulte, Yasemin Armutcuoglu Kaldirim, Feyza Dilber, Osman Cavit Ozdogan, et al.

    Background /Objectives: Biomarkers such as lens agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin, as well as biomarker- and/or clinical-parameter-derived composite models (GALAD, GAAP, ASAP, aMAP, Doylestown), may improve detection in addition to alpha-fetoprotein, yet comparative data across diverse populations remain limited. Methods: In this biobank-based case–control study, we evaluated 562 adults (120 healthy controls, 277 chronic liver disease, 165 hepatocellular carcinoma) from January 2019 to 2024. Diagnostic performance for any-stage and early-stage hepatocellular carcinoma was assessed across three thresholds: Youden-index-derived optimal cut-offs, research-established cut-offs, and cut-offs ensuring 90% specificity. Receiver operating characteristic analysis was performed. Subgroup analyses were stratified by etiology and alpha-fetoprotein status. Results: At optimal cut-offs, GALAD showed the highest sensitivity for any-stage (90.3%) and early-stage (89.1%) hepatocellular carcinoma, with 70–80% specificity. Using established cut-offs, GALAD retained the highest sensitivity for any-stage (75.8%) and early-stage (57.8%) hepatocellular carcinoma, with 93.5% specificity. GALAD demonstrated the best performance in non-viral hepatocellular carcinomas (area under the curve 0.872), whereas GAAP and ASAP showed similarly high area under the curve values in viral etiology (area under the curve 0.955–0.960). Conclusions: Our results demonstrate the consistent performance of the GALAD score across diverse populations and underscore its superiority over individual biomarkers and other composite models. Notably, the GAAP and ASAP scores—which use one less biomarker (AFP-L3)—exhibited comparable performance, particularly in viral etiology. These findings support the integration of the composite biomarker models into tailored hepatocellular carcinoma surveillance strategies.


  • Open Access

    Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

    by Tugce Ozlu Karahan, Elvan Yilmaz Akyuz, Demet Yilmaz Karadag, Yusuf Yilmaz, Fatih Eren

    Background: This randomized controlled study sought to determine the effect of intermittent fasting on anthropometric measurements, fibroblast growth factor (FGF)-21, and autophagy markers, as well as on hepatic steatosis and fibrosis levels in overweight or obese patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: Patients were randomly assigned into two groups: received a dietary treatment involving 22–25 kcal/kg/day of energy for 8 weeks and followed the same dietary intervention and a 16:8 pattern. The extent of hepatic steatosis and fibrosis was determined using transient elastography on a FibroScan® device. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), determined by transient elastography, reflect hepatic steatosis and fibrosis, respectively. In duplicate, serum levels of FGF-21, Beclin-1, and ATG-5 were determined using enzyme-linked immunosorbent assay. Results: The study included 48 patients with a mean age of 48.2 ± 1.4 years (27 female and 21 male). Improvements in anthropometric measurement and CAP and LSM levels and a decrease in serum FGF-21 levels were found in both groups (p < 0.05). Changes in the CAP and FGF-21 levels were higher in the energy + time-restricted diet group (p < 0.05). Autophagy-related protein (ATG)-5 levels increased only in the energy + time-restricted diet group [(0.74 (0.46–1.29) ng/mL vs. 0.95 (0.73–1.32) ng/mL, p = 0.03]. Conclusions: Intermittent fasting was potentially practical in the management of MAFLD. In particular, changes in FGF-21 and ATG-5 levels indicate the potential of intermittent fasting to regulate metabolic processes and autophagy. However, methodological limitations should be taken into consideration when interpreting the study results.


  • Open Access

    Does Genetic Variation in PNPLA3, TM6SF2 and HSD17B13 have a Role in the Development or Prognosis of Hepatocellular Carcinoma in Turkish Patients with Hepatitis B?

    by Coskun Ozer Demirtas, Fatih Eren, Demet Yilmaz, Osman Cavit Ozdogan, Feyza Gunduz

    Background and Aims: Progression to hepatocellular carcinoma (HCC) is restricted by viral suppression in chronic hepatitis B (CHB); however, some patients still progress despite antiviral therapy. Presence of single nucleotide polymorphisms (SNPs) such as PNPLA3 rs738409 and TM6SF2 rs58542926 are associated with the development and progression of steatotic liver disease to HCC, whereas a splice variant in HSD17B13 rs72613567:TA has been shown to be protective. We investigated the role of these SNPs in the development or prognosis of HCC in pure CHB etiology, in the absence of hepatic steatosis, remains unknown. Materials: We analysed PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 SNPs in a prospectively recruited cohort (n=323) consisting of healthy controls, CHB and CHB-HCC patients without hepatic steatosis. SNPs were determined by PCR analysis and associations for the alleles and genotypes were investigated using adjusted-logistic regression analyses. The overall survival (OS) data were collected from CHB-HCC patients for survival analysis. Results: The genotype and allelic distribution of PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 were similar between healthy controls, CHB, and CHB-HCC groups. No genotype, allele or haplotype analysis was found to be associated with increased risk for CHB-HCC. Survival analysis revealed no genotype or allele to be associated with OS in patients with CHB-HCC. Conclusions: We could not demonstrate any association of PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 with the development or prognosis of CHB-HCC, supporting the initial hypothesis that they should be considered specific hotspots for liver diseases characterized with hepatic steatosis.


  • Open Access

    Evaluation of the Association between Programmed Cell Death-1 Gene Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A Pilot Study

    by Abdullah Fatih Demirci, Coskun Ozer Demirtas, Fatih Eren, Demet Yilmaz, Caglayan Keklikkiran, Osman Cavit Ozdogan, Feyza Gunduz

    Background and Aims: Programmed cell death-1 (PD-1) has a vital role in regulating T-cell function, and immune escape mechanism of cancer cells. It was shown that there could be a relationship between single nucleotide polymorphisms (SNPs) in the PD-1 gene and susceptibility to hepatocellular carcinoma (HCC) based on various studies. We aimed to investigate the role of three SNPs within the PD-1 gene in susceptibility to HCC in the Turkish population. Methods: Single nucleotide polymorphisms of PD-1.1, 1.5, and 1.6 were genotyped by using TaqMan Allelic Discrimination Assays in blood samples of 137 HCC and 136 control subjects, matched for age and gender. The genotype, allele and haplotype frequencies were compared in HCC and control groups using logistic regression analysis. Results: Genotype distributions of PD-1.1, PD-1.5 and PD-1.6 SNPs were in Hardy-Weinberg equilibrium. No significant difference was observed in the genotype distribution of PD-1.1, PD-1.5 and PD-1.6 polymorphisms among gender and age-matched HCC (M/F: 96/41; mean age: 61.4 ±11.7 years) and control group (M/F: 94/42; mean age: 61.4±10.1). In the haplotype analysis of PD-1.1/PD-1.5/PD-1.6, no significant difference was found among HCC and control group adjusted for sex and age (all p values>0.1). Conclusion: Our findings, firstly reporting the association of PD-1.5 polymorphism with HCC, and PD-1.1 and PD-1.6 with HCC in the Turkish population, suggest that PD-1 polymorphisms are not predisposing factors for HCC development. Future studies with larger sample sizes and different ethnic populations are required to validate our findings.